Pneumonias & Nosocomial Pneumonias, Urinary Tract Infections, Intra-abdominal Infections, Gynaecological Infections such as endometritis, Skin & Skin Structure Infections, Meningitis, Septicaemia, Empiric treatment for presumed infections in adult patients with febrile neutropenia & other polymicrobial infections.
Carbapenem beta-lactam; Antibacterial
Meropenem is a carbapenem antibiotic for parenteral use . It exerts its bactericidal action by interfering with bacterial cell wall synthesis. It penetrates bacterial cell walls, its high level of stability to all serine beta-lactamases and its marked affinity for the Penicillin Binding Proteins (PBPs.). It shows potent bactericidal activity against a broad spectrum of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.
Adults : In the treatment of pneumonia, UTI, gynaecological infections such as endometritis, skin & skin structure infections- 500 mg IV every 8 hours. In the treatment of nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients, septicaemia- 1 g IV every 8 hours, In cystic fibrosis- doses up to 2 gm every 8 hours, In meningitis- 2 gm every 8 hours. Children : Over 3 months to 12 years - 10 to 20 mg/kg every 8 hours, Children over 50 kg weight, adult dosage should be used, 4 years to 18 years with cystic fibrosis - 25 to 40 mg/kg every 8 hours, In meningitis - 40 mg/kg every 8 hours
Probenecid competes with Meropenem for active tubular secretion and thus inhibits the renal excretion, with the effect of increasing the elimination half-life and plasma concentration of meropenem. Meropenem may reduce serum valproic acid levels. Sub therapeutic levels may be reached in some patients.
Hypersensitivity to this product. As with all beta-lactam antibiotics, rare hypersensitivity reactions have been reported. Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to betalactam antibiotics. The co-administration of Meropenem with potentially nephrotoxic drugs should be considered with caution.
Inflammation, thrombophlebitis, pain at the site of injection, Skin reactions like rash, pruritus, urticaria etc, abdominal pain, nausea, vomiting, diarrhoea,headache, paraesthesiae.
Meropenem should not be used in pregnancy unless the potential benefit justifies the potential risk to the foetus. Meropenem should not be used in breastfeeding women unless the potential benefit justifies the potential risk to the baby.
Accidental overdose could occur during therapy, particularly in patients with renal impairment. Treatment of overdose should be symptomatic. In normal individuals, rapid renal elimination will occur; in subjects with renal impairment, haemodialysis will remove Meropenem and its metabolite.
Vial store in a cool, dry place (below 30oC), away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)